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Bone metastases cause significant morbidity and mortality in late-stage breast cancer patients and are currently
considered incurable. Investigators rely on translational models to better understand the pathogenesis of skeletal
complications of malignancy in order to identify therapeutic targets that may ultimately prevent and treat solid tumor
metastasis to bone. Many experimental models of breast cancer bone metastases are in use today, each with its own
caveats. In this methods review, we characterize the bone phenotype of commonly utilized human- andmurine-derived
breast cell lines that elicit osteoblastic and/or osteolytic destruction of bone in mice and report methods for optimizing
tumor-take inmurinemodels of bonemetastasis.We then provide protocols for four of themost common xenograft and
syngeneic inoculation routes for modeling breast cancer metastasis to the skeleton in mice, including the intra-cardiac,
intra-arterial, orthotopic and intra-tibial methods of tumor cell injection. Recommendations for in vivo and ex vivo
assessment of tumor progression and bone destruction are provided, followed by discussion of the strengths and
limitations of the available tools and translational models that aid investigators in the study of breast cancer metastasis
to bone.
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Introduction
Breast cancer metastasis to the skeleton and subsequent bone
destruction often result in severe bone pain, fragility fractures,
nerve compression syndromes and hypercalcemia of
malignancy resulting in significant morbidity and mortality.1,2
Elucidation of the molecular mechanisms that mediate breast
cancer bonemetastases and cancer-induced bone destruction
has begun to reveal potential therapeutic targets that may lead
to improved patient survival and quality of life; however, further
investigation is necessary to address this currently irreversible
late-stage complication ofmalignancy. Therefore, it is of utmost
importance for investigators to establish well-characterized
in vivo models of breast cancer bone metastasis.
Unlike the study of postmenopausal osteoporosis where the
ovariectomy model is the clear FDA-mandated choice,3 there
are numerous murine models of breast cancer metastasis to
bone, each with its own benefits and limitations. Because
spontaneousmetastasis to the skeleton from primary tumors in
animals is rare,2 and no single model reproduces all of the
genetic and phenotypic changes of human breast cancer bone
metastasis, researchers must select a model or a combination
of models that best suits the aspect of the metastatic disease
that they wish to investigate. Here we (1) identify the most
commonly utilized breast cancer cell lines that elicit osteolytic,
osteoblastic ormixedphenotypes in bone, (2) provideprotocols
for tumor cell inoculation routes that model metastatic disease
in the skeleton and (3) exploremethods for the post-inoculation
monitoring of breast cancer progression in bone.
Modeling osteolytic breast cancer bone metastases
Inoculation of bone trophic tumor cells directly into the blood
stream provides a useful tool for investigating the processes
associated with breast cancer cell homing, colonization and
subsequent metastatic tumor growth and osteolytic lesion
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formation in bone. Intra-cardiac inoculation of human triple
negative MDA-MB-231 adenocarcinoma cells into immune-
compromised mice (i.e., BALB/c nude, MF1 nude and
NOD/SCID) results in tumor cell dissemination through the
arterial vascular system and homing primarily to long bones,
spine, jaw and lungs (Figure 1a; Table 1).4,5 In syngeneic tumor
models where murine-derived cell lines are inoculated into a
murine host, a bone metastatic profile can be observed with
varying degrees of success following intra-cardiac injection of
4T1 or PyMT MMTV mammary cancer cells into immune
competent BALB/c or FVB/N mice, respectively (Table 1).6,7
Visceral metastases, particularly to the lung, can significantly
shorten the life span of a mouse and thus limit the experimental
time frame during which skeletal metastases can be studied
in vivo. MDA-MB-231 and 4T1 cell lines have therefore been
manipulated in the laboratory to produce bone-seeking
sub-lines that favor homing to and colonization of mouse tibiae
and femurs with a reduced propensity to metastasize to the
lung. Bone-seeking sub-lines, often referred to in the literature
as MDA-MB-231-B02, MDA-MB-231-1833, MDA-MB-231-B,
MDA-IVandMDA-MB-231-bone, form tumors in the longbones
of up to 90% of mice following intra-cardiac inoculation in
BALB/c nude mice.8–12 Intra-cardiac inoculation of the subline
4T1-2 cells into BALB/c mice results in bone metastases in
70–80% of animals (Table 1).13
Direct intra-tibial injection of a number of breast cancer cell
lines includingMDA-MB-231,MDA-MB-436 andSUM1315 into
immunocompromisedmice and 4T1 and PyMTMMTV cell lines
into immune competent BALB/c and FVB/N mice results in the
development of osteolytic mammary tumors in bone with
minimal impact outside of bone marrow engraftment
(Figure 1b; Table 1).7,14,15 The intra-tibial model bypasses the
early stages of metastasis including homing to the bone
microenvironment and is therefore useful for a more direct
assessment of tumor–bone interactions, particularly when
interested in studying genetic manipulations of the host or
tumor cells of interest.
Intra-cardiac, intra-arterial and intra-tibial inoculation of
cancer cells provide useful tools for examining the later stages
of breast cancer bone metastasis; however, these afore-
mentioned models do not permit investigation into the stages
that precede the colonization of breast cancer in bone,
including primary tumor growth or the dissemination of tumor
cells through intravazation. The 4T1 mouse mammary cancer
cell line was derived from a BALB/c spontaneous mammary
carcinoma,16 and orthotopic inoculation of 4T1 cells into the
Intra-cardiac MDA-MB-231 Intra-cardiac ZR-751
Intra-tibial 4T1 Intra-tibial MCF-7
Figure 1 Radiographs of the distal femur and proximal tibia of mice with breast cancer bone metastases. Representative images are presented of (a). MDA-MB-231 breast
cancer bone metastases 4 weeks post inoculation of 100 000 cells via intra-cardiac route, (b). ZR-75-1 breast cancer bone metastases 25 weeks post inoculation of 100 000 cells via
intra-cardiac route, (c). 4T1 breast cancer bone metastases 4 weeks post inoculation of 10 000 cells via intra-tibial route, and (d). MCF-7 breast cancer bone metastases 20 weeks
post inoculation of 100 000 cells via intra-tibial route.
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mammary fat pad of BALB/c mice results in spontaneous
metastasis to lungs (B60% of mice) and bone (B20–30% of
mice; Table 1).17 Incidence of bone metastasis can be
increased to 50–70% by utilizing the bone-seeking 4T1-2
subline.18,19 This syngeneicmodel has the benefit of utilizing an
immune competent mouse.
Recently, it was shown that orthotopic inoculation of
luciferase-transduced murine invasive lobular breast
carcinoma cells (KEP cells) resulted in the formation of bone
metastases in the appendicular and axial skeleton within
3 weeks after resection of the orthotopic tumor with minimal
lung involvement in BALBc nude mice (Table 1).20 Although
MDA-MB-231 do not metastasize to murine bone from the
orthotopic site in BALB/c nude and NOD SCID mice, distant
metastases at skeletal sites were observed when using NSG
mice,21 suggesting the importance of NK cells in regulating the
metastatic process.
Spontaneous metastasis of an orthotopic human breast
cancer tumor to bone can be achieved in an immune-
compromised mouse using a unique model that incorporates
human-derived bone X-plants. In recent studies, orthotopic
inoculation of human-derived SUM-1315 or MDA-MB-231-IV
cells into the mammary fat pad of NOD SCID mice 4 weeks
following ectopic implantation of human bone resulted
in spontaneous metastasis of human breast cancer cells
specifically to the human bone grafts in 40–60% of animals
(Table 1).22,23
Modeling osteoblastic breast cancer bone metastases
Although patients with breast cancer usually develop osteolytic
bone metastases, as many as 25% will present with osteo-
blastic bone metastases.24 The human breast cancer cell lines
ZR-75-1 andMCF-7 can be utilized to establish an osteoblastic
bone metastatic phenotype in mice.
ZR-75-1 cultures were initially derived from a malignant
ascetic effusion in a 63-year-old Caucasian female with ductal
carcinoma. ZR-75-1 cells possess receptors for all four classes
of steroid hormones and are thus responsive to estradiol
stimulation.25,26 Mice inoculated via intra-cardiac route with
ZR-75-1 cells develop osteoblastic bonemetastases in the long
bones; however, bone metastases are typically not detectable
by X-ray for 12–25 weeks post inoculation (Figure 1c; Table 2).
Table 1 Human and mouse mammary cancer cell lines that form osteolytic bone lesions following inoculation into mice
Cell line Species Origin Subline Mouse strain Inoculation
route
Metastatic site(s) Time to
lesion
formation
MDA-MB-231 Human Human mammary
adenocarcinoma isolated from a
pleural effusion from a 51-year-old
Caucasian female
Parental BALB/c nude
MF1 nude
NOD/SCID
NSG
Intra-cardiac
Intra-tibial
Orthotopic
Mouse long bones,
spine and jaw
Mouse tibiae
Mouse bones
2–3 weeks
1–3 weeks
7 weeks
MDA-MB-231-BO2 BALB/c nude Intra-cardiac
Intra-tibial
Intra-arterial
Mouse long bones,
spine and jaw
Mouse tibiae
Mouse long bones
2–3 weeks
1–3 weeks
2–3 weeks
MDA-MB-231-IV BALB/c nude Intra-cardiac
Intra-tibial
Intra-arterial
Intra-venous
Orthotopic
Mouse long bones,
spine and jaw
Mouse tibiae
Mouse long bones
Mouse long bones
Human bone
X-plants
2–3 weeks
1–3 weeks
2–3 weeks
2–3 weeks
10–14
weeks
MDA-MB-436 Human Human mammary
adenocarcinoma isolated from a
pleural effusion from a 43-year-old
Caucasian female
Parental MF1 nude
BALB/c nude
NOD/SCID
Intra-osseous Mouse tibiae 2–3 weeks
SUM1315 Human Isolated from a metastatic nodule
of a Caucasian female patient with
ductal carcinoma
Parental NOD/SCID Intra-tibial
Orthotopic
Mouse tibiae
Human bone
X-plants
3–4 weeks
8–12
weeks
4T1 Mouse Isolated from a stage 1V
mammary tumor from a female
BALB/c cfC3H mouse
Parental BALB/c
cfC3H
Intra-cardiac
Intra-tibial
Orthotopic
Mouse long bones,
spine, jaw and lungs
Mouse tibiae
Mouse long bones,
jaw and lungs
2–3 weeks
1–3 weeks
3–6 weeks
4T1-2 BALB/c
cfC3H
Intra-cardiac
Intra-tibial
Orthotopic
Mouse long bones,
spine, jaw and lungs
Mouse tibiae
Mouse long bones,
jaw and lungs
2–3 weeks
1–3 weeks
3–4 weeks
PyMT MMTV Mouse Isolated from mammary tumour
induced by MMTV viral oncogene
in FVB/N female mouse
Parental FVB/N Intra-cardiac
Intra-tibial
Mouse long bones,
spine, jaw and lungs
Mouse tibiae
2–3 weeks
1–2 weeks
KEP Mouse Mouse invasive lobular carcinoma
derived from a Keratin14-driven
E-cadherin/p53 (KEP) knock out
primary mammary carcinoma
KEP/Luc
KEP/Luc
RAG / ;
IL2Rgc /
BALB/c
BALB/c nude
Orthotopic
Intra-cardiac
Orthotopic
Intra-tibial
Spine
Mouse long bones
and spine
Mouse long bones
and spine
Mouse tibiae
3–5 weeks
2–4 weeks
6–9 weeks
2–4 weeks
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Human MCF-7 breast cancer cells were derived from a
metastatic pleural effusion in a 69-year-old Caucasian female
with breast carcinoma.27 MCF-7 cells retain characteristics of
differentiated mammary epithelium and possess estrogen
receptors.27,28 Intra-cardiac inoculation of MCF-7 cells in
immune-compromised mice results in mixed osteolytic/
osteoblastic bone metastases in the long bones after 20–25
weeks (Table 2). In order to speed metastatic progression, the
MCF-7 cell line has been stably transfected with the oncogene
Neu, and this cell line establishes mixed osteolytic and
osteoblastic bone metastases in immunocompromised mice
within 10–12 weeks after intra-cardiac inoculation.29 Because
ERþ MCF-7 cell growth is estrogen dependent mice should be
implanted subcutaneously with slow-release estradiol pellets
(0.25mg) prior to intra-cardiac tumor cell inoculation in order to
more closely mimic a pre-menopausal tumor environment and
speed the progression of tumorgrowth in bone.30,31MCF-7 and
MCF-7/Neu cells are also commonly utilized to establish bone
lesions in mice via the intra-tibial inoculation route, with lesions
developing in a shorter time span of 1–3 weeks post injection
(Figure 1d; Table 2). Estradiol supplementation is typically not
introduced when MCF-7 cells are directly implanted into bone.
Materials and Methods
This section beginsbydetailing recommendations for the preparation of
breast cancer cells and pre-operative care instructions for the handling
of mice prior to inoculation. Four of the most commonly utilized cell
inoculation routes resulting in breast cancer bone metastases are then
described, including lists of necessary materials for each technique.
Recommendations for the post-inoculation monitoring of animals and
assessment of tumor progression in bone in vivo and post mortem are
then described.
Breast cancer cell preparation
Manufacturer specifications should guide the user as to the appropriate
growth conditions for the cell line of interest. As a general rule for all
tumor cell inoculation routes, prepare cells from a fresh batch of low
passage number. Split cells 1–2 days prior to the injections such that
they reachB80% confluence on the day of inoculation. Overcrowding
of tumor cells can affect their metastatic potential in vivo; therefore, cell
confluence prior to inoculation must be monitored judiciously. Wash
flasks briefly with the appropriate cold cell culture media or phosphate-
buffered saline (PBS), trypsinize (0.15% Trypsin EDTA) at 37 1C, and
remove cells with ice-cold media containing 10% fetal bovine serum
(FBS). Centrifuge (200g, 5min) and suspend the cell pellet in ice-cold
PBS for quantitation. Re-suspend the cells at the desired concentration
(Table 3) in cold PBS and keep the cell suspension for no more than
30min on ice until the moment of inoculation. Prepare cells in small
batches (enough for 1–2 cages or 5–10 animals) and keep on ice to
minimize clumping and risk of embolism during the in vivo inoculation.
Because of volumetric limitations of the mouse circulation 100ml is the
recommended injection volume using the intra-cardiac or intra-arterial
routes.
Reagents for tumor cell preparation
(1) PBS (without Ca2þ and Mg2þ )
(2) 0.15% Trypsin EDTA
(3) Cold Dulbecco’s Modified Eagle Medium (or other media) with 10%
FBS
Pre-operative management of mice
For the intra-cardiac, intra-arterial and intra-venousmetastasismodels,
mice are inoculated between 4 and 6 weeks of age, as tumor-take is
markedly reduced after 6 weeks. For the intra-tibial injection, 6- to 8-
week-old mice are typically used, as tibiae of younger mice are small
and difficult to inject accurately. A ketamine/xylazine cocktail
(100mgkg 1 and 10mgkg 1, respectively) or isoflurane (2.5% iso-
flurane at 2–3 lmin 1 O2) may be utilized for anesthesia during the
inoculation of tumor cells depending on the laboratory’s preference.
Many groups, however, experience improved survival rates following
intra-cardiac inoculation with the use of isoflurane (vs ketamine/
xylazine), likely due to increased vascular tone and body temperature. If
the mouse strain selected is furred, it may be important to shave the
mouse at the site of inoculation for better visualization of anatomical
landmarks.
Cellular inoculation routes formodelingbreast cancerbone
metastases in mice
Intra-cardiac inoculation of breast cancer cells. Once a mouse has
been properly anesthetized and is unresponsive to pinch, place it on a
sterile surface in supine position ensuring that the vertebral column is
straight. Tape the forelimbs away from the torso at a slightly angled and
upward position (Figure 2a). Prior to inoculation, clean the chest of the
animal thoroughly with betadine and wipe with an alcohol pad or as per
the institutional standard operating procedures. Once the chest has
been sterilized, gently place one hand on the chest of the mouse to
tighten the skin and mark the top of the sternum and the xyphoid
process (distal sternum) with a permanent marker (Figure 2a). Make a
thirdmark in themiddle of these two landmarks and slightly to your right
(animal’s left) just over theheart in the third intercostal space (Figure2a).
This mark identifies the location of the left cardiac ventricle where you
will insert the needle for tumor cell inoculation.
With intra-cardiac inoculation, prepare the needle by leaving a small
air space in the top of the syringe before slowly drawing up the desired
volumeof cell suspension into the syringe (Figure 2b). This air spacewill
permit a small influx of bright red oxygenated blood into the syringe hub
whenproperly inserted into the left cardiac ventricle. Hold the skin of the
mouse tightwith one handand insert the needle perpendicularly into the
middle marking (Figure 2c). When the needle has entered the left
cardiac ventricle,watch for the pulse of blood to appear in the hubof the
needle. The appearance of air bubbles in the needle hub upon insertion
Table 2 Human mammary cancer cell lines that form osteoblastic bone lesions following inoculation into mice
Cell line Species Origin Subline Mouse strain Inoculation
route
Metastatic site(s) Time to lesion
formation
MCF-7 Human Human mammary adenocarcinoma isolated
from a pleural effusion in a 69-year-old
Caucasian female
Parental BALB/c nude Intra-cardiac
Intra-tibial
Mouse long bones
Mouse tibiae
20–25 weeks
1–3 weeks
MCF-7/Neu BALB/c nude Intra-cardiac
Intra-tibial
Mouse long bones
Mouse tibiae
10–12 weeks
1–3 weeks
ZR-75-1 Human Human ductal carcinoma derived from a
malignant ascetic effusion in a 63-year-old
Caucasian female
Parental BALB/c nude Intra-cardiac Mouse long bones
and spine
12–25 weeks
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indicates that it has likely entered the lungs andwill need to be removed
and repositioned. If youdonot see a redpulse of blood in the needle hub
but are confident that you are in the correct location, you can pull up
slightly on the syringe plunger to verify your position in the cardiac
ventricle. If there is still no visible redpulse, the needle canbe slowly and
slightly adjusted up or down.When small adjustments are futile, remove
and reposition the insertion point completely or set the mouse aside
temporarily. Extended anesthesia can cause vasoconstriction and
reduce the animal’s blood pressure such that the pulse of blood into the
needle’s hub becomes less noticeable.
Once the needle is correctly positioned in the left cardiac ventricle,
inject the cell suspension slowly into the left ventriclebeingcareful not to
move the needle or press it deeper into the thoracic cavity. Keep a close
eye on the cell suspension in the syringe and do not inject the air bubble
at the top of the syringe (Figure 2b). As soon as the cells have been
inoculated, quickly remove the needle, apply slight pressure at the
injection site for a few seconds and place the mouse on a heating pad
until fully awake.Oncemice have fully recovered,monitor their behavior
for 24 h and watch for potential signs of embolism or distress.
Materials for intra-cardiac inoculation
(1) Anesthetized mouse (immune compromised if using human cells)
(2) Cellular suspension
(3) 0.5–1 cc insulin syringe, 27–29G, 0.5 inch
(4) Surgical tape
(5) Betadine and alcohol swabs
(6) Permanent marker
(7) Water recirculating heating pad
Intra-arterial inoculation of breast cancer cells in the tail. Once a
mouse has been anesthetized with isoflurane, place it on a sterile
surface in supinepositionand tape the torsoof themouse to the table for
stability. Use a heating pad or lamp to dilate the vesselswithin the tail for
2–3min in order to facilitate greater easeof inoculation. Alternatively, the
tail can be placed in warm water (30–35 1C). Using an alcohol pad,
disinfect the tail vigorously, which will also help dilate the vessels within
the tail and facilitate inoculation. Keep the tail clinched between the
forefinger and thumb and insert the needle (beveled edge facing up)
horizontally across the proximal section of the tail into the artery
(Figure 3). Once the needle has entered the artery, the opposite hand is
used to retract the syringe plunger slightly to inspect for a tight fitting
within the artery and inspect the barrel of the syringe for a small amount
of blood,whichshould appear at theneedle hub. Thiswill not occur if the
needle has not breached the epithelial membrane of the artery or if the
syringe has protruded through the artery. Once the syringe is properly
Air 
space
Cells
Figure 2 Inoculation of breast cancer cells in the left cardiac ventricle of a mouse. (a) Sterilize the chest of an anesthetized mouse and mark the top of the sternum and the
xyphoid process (distal sternum) with a permanent marker. Make a 3rd mark in the middle of these two landmarks and slightly to your right (animal’s left) just over the heart in the third
intercostal space. (b) Prepare the needle by leaving a small air space in the top of the syringe before slowly drawing up the desired volume of cell suspension into the syringe. This air
space will permit a small influx of bright red oxygenated blood into the syringe hub when properly inserted into the left cardiac ventricle. (c) Once the needle is correctly positioned in
the left cardiac ventricle, inject the cell suspension slowly into the left ventricle being careful not to move the needle or press it deeper into the thoracic cavity.
Ventral 
Tail Artery
Lateral Tail 
Veins
Vertebra
Skin
Dorsal
Ventral
Figure 3 Schematic representation of the tail vasculature of a mouse.
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seatedwithin the artery, depress the plunger slowly in order tominimize
cell lysis resulting from fluid shear. The needle should ideally pierce the
artery just once in order for the cell bolus to be delivered in its entirety.
However, when small adjustments are futile, remove the needle
completely and reposition the insertion point proximally to the initial site
of injection. Once mice have fully recovered, monitor their behavior for
24 h and watch for potential signs of embolism, pain, or distress.
Materials for intra-arterial tail inoculation
(1) Anesthetized mouse (immune compromised if using human cells)
(2) Cellular suspension
(3) 0.5–1 cc insulin syringe, 27–29G, 0.5 inch
(4) Surgical tape
(5) Betadine and alcohol swabs
(6) Water recirculating heating pad
Orthotopic (mammary fat pad) inoculation of breast cancer cells.
Place an anesthetizedmouse in supine position on a sterile surface and
tape the forelimbs and hind limbs away from the torso (Figure 4a). Prior
to inoculation, clean the inguinal surface of the animal thoroughly with
betadine and wipe with an alcohol pad or as per the institutional
standard operating procedures. Using sterile surgical instruments,
createasmall incision in the skinadjacent to the fourthmammary fatpad
(Figures 4b and c). Insert the needle into the fourth mammary gland fat
pad and slowly inoculate the tumor cell suspension (Figures 4d and e;
Supplementary Video 1). The 4th mammary gland fat pad is located at
the intersection of three prominent blood vessels (Figure 4c). Aswith all
techniques, it may be important for investigators to practice and
familiarize themselveswith thenecessary anatomical landmarksprior to
initiation of a multi-animal study. After the injection of cells, close the
wound with 4–6 unconnected sutures, administer an analgesic as per
institutional guidelines and place the mouse on a heating pad until fully
awake.
In order to limit the occurrence of spontaneous tumor metastases to
the lungs when using murine-derived cells (for example, 4T1), primary
tumors can be surgically resected from anesthetizedmicewhen tumors
reachB1 cm3. Animals can then be followed for 3–4 additional weeks
for the development of bone metastases.
Some laboratories have reported that orthotopic implantation
of the human-derived breast cancer cell lines SUM-1315 and
MDA-MB-231-IV into immune-compromised mice can elicit sponta-
neous metastasis to bone when preceded by engraftment of human
bone plugs.22,23 In this model, 5mm bone biopsy cores obtained from
human femoral heads (within 2–4 h of removal from the patient) can be
implanted under the skin on the posterior surface of the animal prior to
tumor cell inoculation in the mammary fat pad. Four weeks after bone
plug implantation, the human bone grafts become vascularized and
bonemarrow resembles that of normalbone.22,23Orthotopic injectionof
human-derived tumor cells can then proceed as described, and the
human bone plugs are then excised at the termination of the study
(B8–14weeks)andevaluatedfor thepresenceofbreastcancermetastases.
Materials for orthotopic inoculation
(1) Anesthetized mouse (immune compromised if using human cells)
(2) Cellular suspension
(3) 0.1 cc Hamilton syringe, 25–27G, 0.5 inch
(4) Tape
(5) Betadine and alcohol swabs
(6) Sterile scissors and forceps
(7) Suture
(8) Water recirculating heating pad
(9) Analgesic
4th mammary gland
Figure 4 Inoculation of breast cancer cells in the 4th mammary fat pad of a mouse.
(a, b) Place an anesthetized mouse in supine position on a sterile surface and tape the
forelimbs and hind limbs away from the torso. Prior to inoculation, clean the inguinal
surface of the animal thoroughly with betadine and alcohol. Using sterile surgical
instruments, create a small incision in the skin adjacent to the 4th mammary fat pad.
(c, d). Insert the needle into the fourth mammary gland fat pad and slowly inoculate the
tumor cell suspension. The fourth mammary gland fat pad is located at the intersection
of three prominent blood vessels. (e) After the injection of cells, close the wound with
4–6 sutures, administer an analgesic as per institutional guidelines and place the mouse
on a heating pad until fully awake.
Ligament
Figure 5 Inoculation of breast cancer cells in the proximal tibia of a mouse. (a) After
sterilizing the hind limbs of an anesthetized mouse, bend the knee to nearly 901. While
holding the hind limb between the thumb and index finger, locate the patellar ligament
between the knee and the tibia, which should be visible through the skin as a white
longitudinal structure. (b) Holding the needle parallel to the tibia in the dominant hand,
push the needle through the center of the patellar ligament and into the proximal end of
the tibia. Resistance will be felt once the needle reaches the bone. Twist the needle
slightly to drill through the growth plate until the needle can be felt giving way. Once
inserted into the bone approximately 2–3 mm, inject the cell suspension slowly and then
withdraw the needle using the same drilling motion used to enter the bone.
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Intra-tibial inoculation of breast cancer cells. Prepare a syringe with
the desired tumor cell suspension and set aside until ready to inject.
After sterilizing the hind limbs, bend the knee to nearly 901 (Figure 5a).
While holding the hind limb between the thumb and index finger, locate
the patellar ligament between the knee and the tibia, which should be
visible through the skin as a white longitudinal structure. Some
laboratories choose to make a 2–3mm incision through the skin on the
knee to more easily visualize the tibia and patellar ligament; however,
with practice this may not be necessary. Holding the needle parallel to
the tibia in the dominant hand, push the needle through the center of the
patellar ligament and into the proximal end of the tibia (Figure 5b).
Resistance will be felt once the needle reaches the bone. Twist the
needleslightly todrill through thegrowthplate until theneedlecanbe felt
givingway. Once inserted into the boneB2–3mm, attempt tomove the
needle slightly fromside to side.When the needle is in the tibia, it will not
be easily moved. If it moves freely from side to side, the needle is most
likely embedded primarily in muscle and the insertion will need to be
repeated. When the needle is accurately placed inside the marrow
cavity of the tibia, inject the cell suspension slowly and then withdraw
the needle using the same drilling motion used to enter the bone. In the
event that the needle becomes clogged when penetrating or drilling
through the top of the tibia, remove the original needle and re-insert a
new needle, trying to follow the route created by the first needle. Once
complete, use the same technique to inject the contralateral tibia with
sterile PBSordesiredvehicle to serve as a shamcontrol. Bleeding rarely
occurs; however, if blood does appear, apply pressure at the site.
Administer an analgesic as per institutional guidelines, place themouse
on a heating pad and monitor until active.
Although cells can be inoculated into the tibia at any age, it is more
difficult to penetrate the tibia in older animals once the growth plates
have mineralized (48-week old). On the other hand, very young mice
can present injection difficulties due to the small size of the tibia; most
laboratories therefore select 4- to 6-week-old mice for the intra-tibial
inoculation route. If themouse strain selected is furred, shave or wet the
hair on the hind limb prior to the inoculation in order to better visualize
the patellar ligament and other landmarks in the knee.
Materials for intra-tibial inoculation
(1) Anesthetized mouse (immune compromised if using human cells)
(2) Cellular suspension
(3) 0.1 cc Hamilton syringe, 25–27G, 0.5 inch
(4) Betadine and alcohol swabs
(5) Water recirculating heating pad
(6) Analgesic
Assessment of tumor progression in bone
Throughout a bone metastasis experiment, mice should be monitored
daily for changes in activity levels, mobility and onset of cachexia,
which is a paraneoplastic syndrome characterized in mice by loss of
body weight, muscle atrophy and weakness, arched appearance and
lethargy.32,33 Mice should be euthanized when410–20% body weight
is lost, tumor progression impairs mobility (for example, long bone
fracture, head-tilt, paraplegia) or an animal appears to be in respiratory
distress. A subset of mice may require euthanasia sooner than other
mice in large studies. With the exception of survival studies, it is
important that mice be euthanized on the same day or as close to the
same day as possible such that the experimental time frame is identical
for all mice, thus permitting an accurate comparison of tumor
progression between groups.
Osteolytic lesion area and abnormal bone remodeling can be
visualized and assessed weekly in vivo using a cabinet X-ray machine
(Figure 6a; Table 4). Because X-ray analysis is an assessment of overt
osteolytic lesion formation and provides only indirect information on
tumor cell growth, cancer cell lines are commonly transfected with
bioluminescent proteins permitting in vivo visualization and quantitation
of tumorgrowth atmetastatic sites usingbioluminescence imaging (BLI;
Table 4).11,20,34 BLI serves as an ideal complement to X-ray analysis of
osteolysis, as it provides information on the presence of extra-skeletal
metastases as well as micrometastases in bone, which precede bone
destruction. Although not utilized to quantitate skeletal tumor burden,
intra-vital microscopy may be useful for studying individual tumor cell
motility and behavior in the bone microenvironment.35
At the termination of the study, mice should be subjected to necropsy
and examined closely for gross evidence of metastatic foci outside of
bone. For an intra-cardiac tumor inoculation study, evidence of tumor
growth in the mediastinum surrounding the heart indicates that tumor
cells were not accurately injected into the left cardiac ventricle, and the
mouse should be excluded from the study. Fix all vital organs for future
analysis. Carefully cut and scrape away skeletal muscle from the
forelimbs, hind limbsand vertebral column, and fix the skeletal samples.
Prior to decalcification of the bones, high-resolution ex vivo bone
microcomputed tomography (mCT) can be performed to assess
osteolytic or osteoblastic bone destruction and BV/TV at the distal
femur, proximal tibia or lumbar vertebrae (Figure 6b).
Following decalcification, paraffin-embedded bone should be
sectioned and stainedwith hematoxylin/eosin (H&E), and tumor burden
(mm2) should be measured in long bones and spine using image
analysis software (Figure 6c). Osteoblast numbers may also be
quantitated in H&E stained sections. Histological sections should also
be stained for tartrate-resistant acid phosphatase activity in order to
assess the total osteoclast number relative to the bone surface and the
osteoclast number at the bone and tumor interface, all of which
are known to increase with cancer-induced osteolysis (Figure 6d;
Table 4).36–37 Finally, serum can be assayed for the presence of bone
turnover markers, hormones, inflammatory factors or growth factors of
interest.
When applicable, quantification of spontaneous metastases to lung,
liver, brain or adrenals can be performed in paraffin-embedded organs
collected at necropsy. For these analyses, 5 mm sections can be cut
every 200mm through the organ and stainedwith H&E. The number and
area of metastatic foci for each section can then be determined using
image analysis software, and results can be expressed as the total
metastatic foci numberperorganandas totalmetastatic areaperorgan.
Discussion
When considering skeletalmetastasismodelswith the intention
of studying breast cancer osteolysis, a common choice is the
intra-cardiac injection of human breast cancer cells in immune-
compromised mice.38–40 Alternatively, these human cells can
be directly implanted into bone, bypassing earlier steps in the
metastatic process. A benefit of the former model is that tumor
cells detected in bone have themselves ‘seeded the soil,’ thus
replicating the more natural progression of disseminated tumor
cells formation ofmicrometastases, which progress in size over
time, as occurs in humans. The necessity of using immune
cell-deficientmicewhen inoculating human cell lines is typically
seen as a limitation because it does not accurately model the
immune competent human patient. It can, however, be seen as
an advantage, as it eliminates possible confounding effects
related to the animal’s immune response and permits the study
of human cells in a very permissive host environment.
The pathogenesis of breast cancer bone destruction in the
intra-cardiac MDA-MB-231 model is relatively similar to
the human condition. Upon inoculation, breast cancer cells
circulate in the vasculature, home to the bone compartment,
andmicrometastases can be detected by BLI in distant skeletal
sites in as early as 1 week after injection.41 As the tumor cells
proliferate in the bone microenvironment, tumor-derived
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Figure 6 The assessment of tumor progression in bone can be carried out by (a) quantitation of osteolytic lesion area by X-Ray, (b) measurement of bone volume fraction
(BV/TV) by bone high-resolution microcomputed tomography (mCT), (c) histological assessment of tumor area using hematoxylin/eosin (H&E) staining of long bones and vertebrae
and (d) quantitation of tartrate-resistant acid phosphatase (TRAcP)þ osteoclasts.
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osteolytic factors stimulate osteoclastic bone resorption and
the development of bone lesions, which are quantifiable by
X-ray. The most substantial bone destruction tends to occur in
themetaphyses of the distal femur and proximal tibia, likely due
to the high vascularization andmetabolic activity characteristic
of these trabecular bone compartments.42
Estrogen receptor (ER)þ MCF-7 cells and triple negative
MDA-MB-231 cells are two of the most commonly studied
human breast cancer cell lines.40 Although ERþ primary
tumors have a high propensity to metastasize to bone in
patients,43 ERþ MCF-7 cells are utilized less frequently in
models of breast cancer bone metastasis, as tumor-take can
be limited using the intra-cardiac inoculation route, and
MCF-7 cells require a longer time to develop osteolytic and
osteoblastic lesions.44,45 In contrast, ER MDA-MB-231 cells
readily metastasize to bone and develop osteolytic lesions as
early as 2–3 weeks post inoculation.39 In defense of the use of
an ER cell line, it should also be noted that there is a large
discordance between the ER status of primary tumors and the
ER status of the bone metastatic tumors in patients.43
The intra-tibial inoculation method is ideal for modeling the
final stages of breast cancer bone metastasis and for studying
direct interactions between tumor cells and the bone micro-
environment without concerns about differential tumor-take
from animal to animal. Murine-derived 4T1 cell proliferation in
the tibia and subsequent development of osteolytic lesions can
occurwith the injectionof as fewas10 000murine-derivedcells.
At higher cellular concentrations (50 000–200000 cells), our
laboratories have observed 4T1 cell metastasis to contralateral
tibiae, femurs, forelimbs and the lungs, often limiting the
duration and utility of the model. As with all techniques pre-
sented here, it is recommended that investigators thoroughly
characterize their cell line and inoculation route of choice by
conducting dose–response studies in order to establish the
optimal protocols prior to embarking on large animal trials.
Inoculation of cancer cells into the tail vein is a well-
established bone metastasis model for multiple myeloma.46,47
Our laboratories and others have found that the injection of
breast cancer cells into the tail vein results almost exclusively in
lung metastases, with limited tumor-take in bone.22,48 When
skeletal metastases are desired, we therefore recommend
utilization of the tail artery as the tumor inoculation route for
breast cancer models.22,48–52
In addition to specific limitations related to model choice
discussed above, standard methodologies used by bone
metastasis researchers to assess bone destruction and tumor
burden have their own limitations. Osteolytic lesion area
and tumor burden area in bone are typically assessed by
measurement of X-Ray scan or by serial histological sectioning,
respectively, and are thus merely two-dimensional approx-
imations of three-dimensional tumors. Improvement in imaging
has enhanced sensitivity of detection and yields more accurate
Table 4 Principal end points used to characterize the development of bone metastases in mice
Type Frequency
In vivo analyses
Activity levels and hind limb mobility Daily
Respiratory distress Daily
Symptoms of cachexia Daily
X-ray analysis of osteolytic lesions Weekly or bi-monthly
Bioluminescence imaging (BLI; if applicable) Weekly or bi-monthly
Type Endpoint
Post-mortem analyses
Gross dissection Inspection for visceral metastases in lung, liver, adrenals and brain tissue
Bone microcomputed
tomography (mCT)
Trabecular bone volume/total volume (BV/TV) of the proximal tibia, distal femur and lumbar vertebrae
Histomorphometric analysis of
bone
Tartrate-resistant acid phosphatase (TRAcP) staining of bone
Osteoclast number/bone surface (OcN/BS)
Osteoclast surface/bone surface (OcS/BS)
Osteoclast number at the bone–tumor interface
Hematoxylin/eosin (H&E) staining of bone for BV/TV and osteoblast number/bone surface (ObN/BS)
Tumor characterization H&E staining of forelimbs, hind limbs and spine for total tumor area in bone
Immunohistochemical staining for proteins of interest (e.g., cytokeratin, phospho-smads)
H&E staining of visceral organs for quantitation of soft tissue metastases
Serum factors Biomarkers, if applicable (e.g., bone turnover markers, hormones, inflammatory factors, growth factors,
tumor-derived factors)
Table 3 Preparation of breast cancer tumor cells for inoculation in mice
Inoculation route Cell number Volume (PBS) Syringe/needle
Intra-cardiac 100000 100ml 0.5–1 cc insulin/27–29G, 0.5 inch
Intra-arterial (tail) 100000 100ml 0.5–1 cc insulin/7–29G, 0.5 inch
Orthotopic 100 000–500000 10–20ml 0.1 cc Hamilton/25–27G, 0.5 inch
Intra-tibial 10 000–250000 10–20ml 0.1 cc Hamilton/25–27G, 0.5 inch
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quantification of metastases. Typically, BLI using codon-
optimized luciferase-labeled cells yields higher detection than
fluorescent imaging using GFP-labeled cells.53 Small animal
imaging of bone has forged ahead with the development of
high-resolution in vivo mCT scanners54 in combination with
BLI.55 However, the bone metastasis research community has
been slower to adopt such methodologies. One reason for this
is that cumulative radiation exposure from CT scanners has
been found to enhance metastases56 and thus could confound
cancer metastasis models if radiation exposure is not mon-
itored judiciously.
Despite their limitations and caveats, the established murine
models of breast cancer bone metastases have proven to be
excellent tools for the study of bone and cancer cross talk and
for the evaluation of potential therapeutics that prevent cancer
progression and disrupt the cycle of bone destruction driven by
metastasis.
Multimedia
The following article documents and visually demonstrates
intra-cardiac and intra-tibial inoculation of cancer cells in mice
and also demonstrates representative experimental end points
of bone metastasis: http://www.jove.come/video/4260.
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